1.63
price up icon10.14%   0.15
pre-market  プレマーケット:  1.71   0.08   +4.91%
loading

Invivyd Inc (IVVD) 最新ニュース

pulisher
Feb 09, 2026

Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Feb 09, 2026
pulisher
Feb 09, 2026

Invivyd prices $125M stock offering at $2.50 per share - MSN

Feb 09, 2026
pulisher
Feb 04, 2026

Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD) and Pfizer (PFE) - The Globe and Mail

Feb 04, 2026
pulisher
Feb 04, 2026

H.C. Wainwright reiterates Buy rating on Invivyd stock amid FDA feedback - Investing.com Nigeria

Feb 04, 2026
pulisher
Feb 03, 2026

Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial - Investing.com Nigeria

Feb 03, 2026
pulisher
Feb 03, 2026

Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial By Investing.com - Investing.com South Africa

Feb 03, 2026
pulisher
Feb 03, 2026

Invivyd rises as FDA agrees with late-stage trial design for COVID-19 therapy - Seeking Alpha

Feb 03, 2026
pulisher
Feb 03, 2026

Invivyd aligns with FDA for Phase 3 vaccine trial - Traders Union

Feb 03, 2026
pulisher
Feb 03, 2026

Invivyd rises on late-stage trial testing COVID antibody against mRNA vaccines - TradingView

Feb 03, 2026
pulisher
Feb 03, 2026

Invivyd, Inc. Announces FDA Alignment on LIBERTY Phase 3 Clinical Trial for VYD2311, a Monoclonal Antibody Candidate for COVID-19 Prevention - Quiver Quantitative

Feb 03, 2026
pulisher
Feb 03, 2026

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration - The Manila Times

Feb 03, 2026
pulisher
Feb 03, 2026

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 ... - Caledonian Record

Feb 03, 2026
pulisher
Feb 03, 2026

FDA asks Invivyd to track myocarditis in new COVID antibody vs vaccine trial - Stock Titan

Feb 03, 2026
pulisher
Feb 01, 2026

Invivyd Reports Strong Q3 Growth and Strategic Advances - MSN

Feb 01, 2026
pulisher
Jan 30, 2026

Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update - MarketBeat

Jan 30, 2026
pulisher
Jan 29, 2026

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk - simplywall.st

Jan 29, 2026
pulisher
Jan 27, 2026

Institutional investors in Invivyd, Inc. (NASDAQ:IVVD) see US$113m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st

Jan 27, 2026
pulisher
Jan 26, 2026

Invivyd shares edge higher on education campaign with Olympic star Lindsey Vonn - MSN

Jan 26, 2026
pulisher
Jan 26, 2026

HC Wainwright Predicts Invivyd FY2030 Earnings - MarketBeat

Jan 26, 2026
pulisher
Jan 24, 2026

How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) - Yahoo Finance

Jan 24, 2026
pulisher
Jan 23, 2026

H.C. Wainwright reaffirms Buy rating on Invivyd stock ahead of key trial data By Investing.com - Investing.com Nigeria

Jan 23, 2026
pulisher
Jan 23, 2026

Aug Fed Impact: Should you avoid Invivyd Inc stock right now2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 23, 2026

H.C. Wainwright reaffirms Buy rating on Invivyd stock ahead of key trial data - Investing.com

Jan 23, 2026
pulisher
Jan 23, 2026

Analysts Are Bullish on These Healthcare Stocks: Invivyd (IVVD), Alignment Healthcare (ALHC) - The Globe and Mail

Jan 23, 2026
pulisher
Jan 23, 2026

Invivyd partners with ski champion Lindsey Vonn on antibody education By Investing.com - Investing.com Nigeria

Jan 23, 2026
pulisher
Jan 22, 2026

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com

Jan 22, 2026
pulisher
Jan 22, 2026

Invivyd partners with ski champion Lindsey Vonn on antibody education - Investing.com

Jan 22, 2026
pulisher
Jan 22, 2026

Invivyd stock rises after partnering with Olympic champion Lindsey Vonn By Investing.com - Investing.com Canada

Jan 22, 2026
pulisher
Jan 22, 2026

Invivyd partners with Lindsey Vonn to educate Americans on antibodies and disease prevention - marketscreener.com

Jan 22, 2026
pulisher
Jan 22, 2026

Invivyd Announces Partnership with World Champion Skier - GlobeNewswire

Jan 22, 2026
pulisher
Jan 22, 2026

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention - Finviz

Jan 22, 2026
pulisher
Jan 21, 2026

Invivyd stock maintains Buy rating at BTIG on Long COVID treatment potential - Investing.com UK

Jan 21, 2026
pulisher
Jan 21, 2026

Invivyd stock maintains Buy rating at BTIG on Long COVID treatment potential By Investing.com - Investing.com Nigeria

Jan 21, 2026
pulisher
Jan 21, 2026

Invivyd to begin phase 2 trial of antibody therapy for long COVID - Investing.com Nigeria

Jan 21, 2026
pulisher
Jan 21, 2026

Invivyd to begin phase 2 trial of antibody therapy for long COVID By Investing.com - Investing.com South Africa

Jan 21, 2026
pulisher
Jan 20, 2026

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - The Manila Times

Jan 20, 2026
pulisher
Jan 20, 2026

Invivyd Initiates Phase 2 Trial for VYD2311 Targeting Long COVID Patients - Intellectia AI

Jan 20, 2026
pulisher
Jan 20, 2026

Experimental COVID antibody trial targets Long COVID and vaccine injury by 2026 - Stock Titan

Jan 20, 2026
pulisher
Jan 19, 2026

Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Grows By 24.4% - MarketBeat

Jan 19, 2026
pulisher
Jan 18, 2026

Bull Run: What is the target price for Invivyd Inc stockMarket Volume Summary & Safe Entry Trade Reports - baoquankhu1.vn

Jan 18, 2026
pulisher
Jan 15, 2026

Invivyd, Inc.'s (NASDAQ:IVVD) Business Is Trailing The Industry But Its Shares Aren't - 富途资讯

Jan 15, 2026
pulisher
Jan 15, 2026

Invivyd, Inc. (NASDAQ:IVVD) Given Average Rating of "Hold" by Brokerages - MarketBeat

Jan 15, 2026
pulisher
Jan 14, 2026

​Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 - Insider Monkey

Jan 14, 2026
$44.21
price up icon 0.36%
$27.35
price down icon 1.16%
$100.05
price down icon 8.24%
$108.93
price down icon 1.28%
$148.55
price down icon 0.66%
biotechnology ONC
$353.43
price up icon 1.31%
大文字化:     |  ボリューム (24 時間):